title: An open-label clinical trial evaluating safety and pharmacokinetics of two dosing schedules of panitumumab in patients with solid tumors.
abstract: OBJECTIVE
  This study evaluated safety, pharmacokinetics, and efficacy of 2 dose schedules and 2 infusion times of panitumumab in patients with advanced solid malignancies.
  
  
  METHODS
  This phase I multicenter, open-label study sequentially enrolled patients with advanced solid tumors refractory to standard therapy, or for which no standard therapy exists, to receive panitumumab 6 mg/kg every 2 weeks or 9 mg/kg every 3 weeks. Patients receiving panitumumab every 2 weeks received either all infusions over 60 minutes or a 60-minute infusion for the first dose followed by 30-minute infusions if the first infusion was well tolerated. Patients in the every-3-week cohort received 60-minute infusions. Safety outcomes included the incidence of adverse events and antipanitumumab antibody formation. Pharmacokinetic properties were determined. Efficacy endpoints included response rate and duration of response.
  
  
  RESULTS
  Eighty-six patients were enrolled; 84 (98%) received panitumumab. Treatment-related adverse events occurred in 90% of patients. Safety profiles were similar between patients receiving 30-minute (n = 20) and 60-minute (n = 43) infusions every 2 weeks and patients receiving panitumumab every 3 weeks (n = 21). Panitumumab exposure at steady state increased dose proportionally, and peak serum concentrations were similar in patients receiving either 30- or 60-minute infusions every 2 weeks. Objective responses were seen in 4 patients (5%) with colon, rectal, esophageal, and bladder cancers.
  
  
  CONCLUSIONS
  Similar drug exposures and safety profiles were observed in patients receiving panitumumab 6 mg/kg every 2 weeks with either 30- or 60-minute infusions and antitumor activity was seen in some patients. Exposure increased approximately dose proportionally at steady state.
authors.affiliation: Cancer Centers of the Carolinas, Greenville, SC 29605, USA. joe.stephenson@usoncology.com
authors.forename: Joe J
authors.initials: JJ
authors.lastname: Stephenson
authors.forename: Charles
authors.initials: C
authors.lastname: Gregory
authors.forename: Howard
authors.initials: H
authors.lastname: Burris
authors.forename: Tim
authors.initials: T
authors.lastname: Larson
authors.forename: Udit
authors.initials: U
authors.lastname: Verma
authors.forename: Allen
authors.initials: A
authors.lastname: Cohn
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Crawford
authors.forename: Roger B
authors.initials: RB
authors.lastname: Cohen
authors.forename: Julie
authors.initials: J
authors.lastname: Martin
authors.forename: Peggy
authors.initials: P
authors.lastname: Lum
authors.forename: Xinqun
authors.initials: X
authors.lastname: Yang
authors.forename: Rafael G
authors.initials: RG
authors.lastname: Amado
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D004305:Dose-Response Relationship, Drug; D023381:Endpoint Determination; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D000077544:Panitumumab; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000077544:Panitumumab